Reslizumab subcutaneous (SC) vs placebo
Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma
Reslizumab subcutaneous (SC) showed no clear difference in rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).
1 finding from 1 review
- Rate ratio 0.79 [0.56, 1.11]1 study · 464 participantsHigh